Marcus Estafanous, MD
Retina Specialist · Farrell, PANPI 1437151743
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (55.0%), royalties or licence payments and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Bausch & Lomb, A Division Of Bausch Health US, LLC at 31.6% of the total.
Across 94 payments — averaging $37.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb, A Division Of Bausch Health US, LLC$1K
- Bausch & Lomb Americas Inc.$891
- Regeneron Healthcare Solutions, Inc.$745
- Alimera Sciences, Inc.$164
- Apellis Pharmaceuticals, Inc.$151
- Genentech USA, Inc.$143
- plus $293 from 7 others
What the payments were for
- Royalty or licence$1,55745%
- Food & beverage$1,91855%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 15 | $1,103 |
| Bausch & Lomb Americas Inc. | 21 | $891 |
| Regeneron Healthcare Solutions, Inc. | 28 | $745 |
| Alimera Sciences, Inc. | 5 | $164 |
| Apellis Pharmaceuticals, Inc. | 5 | $151 |
| Genentech USA, Inc. | 6 | $143 |
| Astellas Pharma US Inc | 5 | $125 |
| AbbVie | 4 | $81 |
| ANI Pharmaceuticals, Inc. | 1 | $24 |
| Novartis | 1 | $20 |
| Optos, Inc. | 1 | $18 |
| Mallinckrodt Hospital Products Inc. | 1 | $14 |
| Omeros Corporation | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,488 in reported general payments places this provider in the 65th percentile of 43 retina specialist providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 174 | $5,507 |
| Ketorolac Tromethamine | 98 | $2,229 |
| Brimonidine Tartrate | 13 | $1,049 |
| Ciprofloxacin Hcl | 69 | $639 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 16 | $361 |
| Dorzolamide Hcl | 13 | $190 |
| Latanoprost | 12 | $100 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Farrell
- Joshua GreenePhiladelphia$394K
- Jay ChhablaniPittsburgh$70K
- Sachin PatelPottsville$17K
- Brian VanderbeekPhiladelphia$14K
- Thucanh MultererFogelsville$9K
- Christopher BairHermitage$9K
- Albert MaguirePhiladelphia$9K
- Hugo LinaresPhiladelphia$7K
- Moiz CarimWyomissing$6K
- Salman PorbandarwallaLancaster$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.